Last reviewed · How we verify
Renacidin (GLUCONOLACTONE)
Renacidin (generic name: GLUCONOLACTONE) is a Calculi Dissolution Agent [EPC] Small molecule drug developed by United Guardian. It is currently FDA-approved (first approved 1990) for Urinary bladder stone.
At a glance
| Generic name | GLUCONOLACTONE |
|---|---|
| Sponsor | United Guardian |
| Drug class | Calculi Dissolution Agent [EPC] |
| Target | Glucosylceramidase |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Urinary bladder stone
Common side effects
- Bladder irritability
- Chemical cystitis
- Transient burning sensation in the bladder
Key clinical trials
- Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced (PHASE2)
- The Influence of Personal Care Products on the Skin Microbiome (NA)
- The Influence of Probiotics in a Drinkable Yogurt on Skin Health (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Renacidin CI brief — competitive landscape report
- Renacidin updates RSS · CI watch RSS
- United Guardian portfolio CI
Frequently asked questions about Renacidin
What is Renacidin?
Renacidin (GLUCONOLACTONE) is a Calculi Dissolution Agent [EPC] drug developed by United Guardian, indicated for Urinary bladder stone.
What is Renacidin used for?
Renacidin is indicated for Urinary bladder stone.
Who makes Renacidin?
Renacidin is developed and marketed by United Guardian (see full United Guardian pipeline at /company/united-guardian).
What is the generic name of Renacidin?
GLUCONOLACTONE is the generic (nonproprietary) name of Renacidin.
What drug class is Renacidin in?
Renacidin belongs to the Calculi Dissolution Agent [EPC] class. See all Calculi Dissolution Agent [EPC] drugs at /class/calculi-dissolution-agent-epc.
When was Renacidin approved?
Renacidin was first approved on 1990.
What development phase is Renacidin in?
Renacidin is FDA-approved (marketed).
What are the side effects of Renacidin?
Common side effects of Renacidin include Bladder irritability, Chemical cystitis, Transient burning sensation in the bladder.
What does Renacidin target?
Renacidin targets Glucosylceramidase and is a Calculi Dissolution Agent [EPC].
Related
- Drug class: All Calculi Dissolution Agent [EPC] drugs
- Target: All drugs targeting Glucosylceramidase
- Manufacturer: United Guardian — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Urinary bladder stone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing